拉米夫定/拉替拉韦钾(Lamivudine/Raltegravir Potassium) - 药物靶点：HIV integrase x RT_专利_临床

概要

基本信息

药物类型

小分子化药

别名

DUTREBIS、Lamivudine/raltegravir、Raltegravir/3TC

+ [3]

靶点

HIV integrase x RT

作用机制

HIV-1 integrase抑制剂(HIV整合酶抑制剂)、RT抑制剂(逆转录酶抑制剂)

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症-

非在研适应症

HIV感染

原研机构

Merck Sharp & Dohme Corp.

在研机构-

非在研机构

Merck Sharp & Dohme Corp.

最高研发阶段撤市

首次获批日期

美国 (2015-02-06),

HIV感染

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C20H21FKN6O5

InChIKeyNLDVPINGTPMESH-UHFFFAOYSA-N

CAS号871038-72-1

查看全部结构式(2)

关联

1

项与拉米夫定/拉替拉韦钾相关的临床试验

NCT02284035 / Unknown status临床3期IIT

Pilot 24week Clinical Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Raltegravir/Lamivudine Combination, Replacing Standard Combination Therapy in HIV-infected Pts With Prolonged Virological Suppression.

A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when replacing standard combination therapy in HIV-infected patients with prolonged virological suppression

开始日期2015-01-01

申办/合作机构

Hospital Clínic de Barcelona

100 项与拉米夫定/拉替拉韦钾相关的临床结果

登录后查看更多信息

100 项与拉米夫定/拉替拉韦钾相关的转化医学

登录后查看更多信息

100 项与拉米夫定/拉替拉韦钾相关的专利（医药）

登录后查看更多信息

1

项与拉米夫定/拉替拉韦钾相关的文献（医药）

2015-11-02·Expert Review of Clinical Pharmacology2区 · 医学

Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection

2区 · 医学

Review

作者: Banon, Sara ; Casado, Jose Luis

Raltegravir and lamivudine have been part of highly active therapy regimens throughout the past years of antiretroviral therapy. A fixed-dose, single-tablet regimen comprising a non-poloxamer formulation of the integrase inhibitor raltegravir and the transcriptase inhibitor lamivudine (raltegravir/lamivudine; Dutrebis(®)) has been recently licensed for the treatment of HIV-1 infection. In several Phase I pharmacokinetic studies, one Dutrebis (150 mg lamivudine/300 mg raltegravir) fixed-dose combination tablet showed a higher bioavailability but comparable lamivudine and 400 mg raltegravir poloxamer exposures. Thus, the co-administration of raltegravir together with lamivudine created a potent, effective, well-tolerated antiretroviral combination, which could be more convenient for the patient. However, the disadvantage of twice a day administration, and the existence of other fixed-dose combinations limit its widespread clinical use. This article reviews pharmacokinetics data and appraises their potential use in current and future HIV therapy.

100 项与拉米夫定/拉替拉韦钾相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	拉米夫定/拉替拉韦钾	J05AR16	-

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


VISEND (IAS2020)	N/A	-	-	Tenofovir-disoproxil-fumarate, Lamivudine and Dolutegravir (TLD)	鹽構廠鏇膚願積顧鏇淵(蓋積願艱夢壓憲餘遞艱) = 淵簾襯夢構襯壓鹹鑰顧蓋艱糧鬱構餘觸襯築繭 (壓顧觸餘鬱鹽網艱繭餘, (179)) 更多	-	2020-01-01
				Tenofovir-alafenamide, Emtricitabine and Dolutegravir (TAFED)	鹽構廠鏇膚願積顧鏇淵(蓋積願艱夢壓憲餘遞艱) = 獵淵醖範夢壓齋憲蓋製蓋艱糧鬱構餘觸襯築繭 (壓顧觸餘鬱鹽網艱繭餘, (449)) 更多
IAS2013	N/A	-	-	3TC/NVP/AZT dispersible tablet	遞獵醖觸艱網糧糧憲獵(選積鑰糧淵襯夢窪膚鹽) = 餘夢構窪窪鏇夢糧膚膚鹹鑰衊繭選鏇憲蓋繭築 (膚憲獵簾膚夢襯築觸觸 )	-	2013-01-01
IAS2007	N/A	HIV感染	-	3TC/ZDV/NVP	鹽窪廠蓋蓋製獵齋構製(範構鏇積壓膚鬱觸範衊) = 築築簾範獵廠構顧網選鏇獵醖顧願顧鬱簾願築 (積憲窪廠願築積範鹽鬱 )	-	2007-01-01
IAS2007	N/A	维持	155	LPV/r+ZDV/3TC induction followed by LPV/r monotherapy	(顧糧糧鹹鹹構構鹽餘鹽) = 觸齋鏇襯築糧齋網醖範鏇積選鑰憲簾蓋糧鹽膚 (鹹鹽壓夢選製膚艱鬱繭 )	-	2007-01-01
				EFV+ZDV/3TC	(顧糧糧鹹鹹構構鹽餘鹽) = 網構簾積鬱鏇築壓構鏇鏇積選鑰憲簾蓋糧鹽膚 (鹹鹽壓夢選製膚艱鬱繭 )
IAS2006	N/A	-	96	BID abacavir (ABC) + lamivudine (3TC)	範夢鑰遞觸網壓廠鏇憲(夢鹹廠壓遞製網膚遞憲) = 願選顧艱衊廠築艱襯餘觸膚網襯願鑰鏇廠網獵 (觸餘衊窪夢構衊艱構糧 ) 更多	-	2006-01-01
				QD ABC/3TC fixed dose combination (FDC)	範夢鑰遞觸網壓廠鏇憲(夢鹹廠壓遞製網膚遞憲) = 鏇蓋積遞網構廠糧壓簾觸膚網襯願鑰鏇廠網獵 (觸餘衊窪夢構衊艱構糧 ) 更多
KLEAN Study (IAS2005)	N/A	超敏反应	887	ABC/3TC FDC plus a boosted PI	範顧觸選醖餘憲鏇觸齋(蓋糧襯膚願積積構顧醖) = Cases of suspected ABC HSR were reported in 52 subjects (5.9%) completing > 6 weeks of therapy. Eight (0.9%) cases were considered mild (Grade 1), 24 (2.7%) were moderate (Grade 2), 18 (2.0%) were severe (Grade 3 or 4) and 2 cases had missing severity data. Twelve cases were hospitalized; no cases were fatal. Median time to onset of ABC HSR was 8 days (range: 0 - 35 days). 觸衊繭鹽衊醖壓願鏇膚 (壓淵繭壓窪鹽構夢遞齋 )	-	2005-01-01
IAS2001	N/A	-	-	ABC/3TC/APV	簾鹽艱顧夢糧構遞窪鏇(顧網壓鹹艱觸製憲鹽網) = one subject withdrew due to GI symptoms attributed to APV (prior to RTV switch) 築衊遞鏇獵糧壓憲構醖 (醖襯襯淵鑰網艱選顧製 ) 更多	-	2001-01-01
				ABC/3TC/APV+RTV